Mersana Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical firm, will present at two upcoming investor conferences. These include the TD Cowen 5th Annual Oncology Innovation Summit on May 29, 2024, at 9:00 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:00 a.m. ET. The company specializes in developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.

Mersana's proprietary ADC platforms, Dolasynthen and Immunosynthen, support a pipeline of product candidates such as XMT-1660 and XMT-2056. Live webcasts and archived replays of these events will be accessible on Mersana's website for 90 days post-event.

Positive

• Mersana to present at two influential investor conferences, enhancing visibility.
• The company's focus on ADCs addresses high unmet medical needs in cancer treatment.
• Proprietary platforms Dolasynthen and Immunosynthen are generating a promising pipeline.
• Live webcasts and archived replays will enhance accessibility for investors.

Negative

• No new financial data or clinical trial results were disclosed.
• Presentations at conferences do not guarantee immediate financial impact.
• The announcement may not directly address existing shareholder concerns or uncertainties.

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

• TD Cowen 5th Annual Oncology Innovation Summit
  Format:        Fireside chat
  Date/Time:        Wednesday, May 29, 2024, at 9:00 a.m. Eastern Time
  
  
• Goldman Sachs 45th Annual Global Healthcare Conference
  Format:         Fireside chat
  Date/Time:        Wednesday, June 12, 2024, at 8:00 a.m. Eastern Time
  

Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When will Mersana Therapeutics present at the TD Cowen 5th Annual Oncology Innovation Summit?

Mersana Therapeutics will present on May 29, 2024, at 9:00 a.m. ET.

What is the focus of Mersana Therapeutics' pipeline?

Mersana focuses on developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.

Where can I watch the webcasts of Mersana's presentations?

Live webcasts will be available on the Investors & Media section of Mersana's website.

What ADC platforms does Mersana Therapeutics use for their pipeline?

Mersana uses proprietary Dolasynthen and Immunosynthen ADC platforms.

Will there be replays available for Mersana's conference presentations?

Yes, archived replays will be available for approximately 90 days following the events.

What are Mersana's key product candidates mentioned in the press release?

Key product candidates include XMT-1660 and XMT-2056.